SCHEMBL1341697

SCHEMBL1341697

O=C1CN(C(=O)/C=C/c2cccc(Cl)c2)CCN1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.69
GAA P10253 2/20 0.69
RAB9A P51151 2/20 0.69
LMNA P02545 4/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 1/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP1A2 P05177 3/20 0.51
CYP2C9 P11712 2/20 0.51
NPC1 O15118 1/20 0.47
MAOB P27338 2/20 0.46
CYP2D6 P10635 2/20 0.45
CYP1A1 P04798 1/20 0.45
CYP1B1 Q16678 1/20 0.45
ITGB2 P05107 1/20 0.44
ICAM1 P05362 1/20 0.44
ITGAL P20701 1/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341698 1.00 SMN1; SMN2 (0.69) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL1556451 0.89 RAB9A (0.55) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL1556455 0.89 RAB9A (0.55) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL22633477 0.85 RAB9A (0.58) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL11484136 0.85 CYP1A2 (0.62) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL22633478 0.85 RAB9A (0.58) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL11484142 0.85 CYP1A2 (0.62) SMN1; SMN2GAARAB9ALMNAMEN1
SCHEMBL1344179 0.85 RAB9A (0.65) SMN1; SMN2GAARAB9ALMNAKDM4E
SCHEMBL1344182 0.85 RAB9A (0.65) SMN1; SMN2GAARAB9ALMNAKDM4E
SCHEMBL11618537 0.80 CYP1A2 (0.66) SMN1; SMN2GAARAB9ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063042-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2220055-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-08-25 EP disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023713-A1 HETEROCYCLIC COMPOUNDS CCR5, CCR3, CCR2 SMN1; SMN2 4301/4885GAA 4779/4885RAB9A 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.